In March 2024, Viking Therapeutics announced positive results from the company's Phase I multiple ascending dose (MAD) clinical trial of an oral tablet formulation of VK2735 , a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, in development for the potential treatment of metabolic disorders such as obesity
leer el artculo Dominar la alimentacin navidea: un enfoque de medicina funcional Medicina funcional Una gua para mantener hbitos alimentarios saludables durante las fiestas navideas, con consejos sobre el control de las porciones, la alimentacin consciente, la incorporacin de alternativas saludables y la importancia del ejercicio, la hidratacin y la moderacin con el alcohol
It is our unique technology, the highest power of our battery is 100C
Managing their weight and blood sugar
The mechanism of action involves mimicking two naturally occurring incretin hormones that regulate glucose metabolism and appetite
A 2023 preclinical study tested semaglutide specifically in an MS model and found it improved cognitive and motor function, reduced nerve damage, and promoted nerve repair
